FXS is a Common Inherited Form of Autism
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to SPG601 for the treatment of people with Fragile X syndrome (FXS), a condition for which there is currently no approved medicine.
Health Technology Insights: AAMI Aligns With National Academy of Medicine AI Code of Conduct
FXS, a known cause of autism, is the leading inherited form of intellectual disability caused by the silencing of the Fmr1 gene. FXS can produce a wide range of disabling symptoms, with many individuals requiring lifelong around-the-clock supportive care.
SPG601 works at the synaptic level, targeting a well-established molecular dysfunction in FXS, addressing core symptoms to improve challenging behaviors and the overall quality of life of those affected. It is a small molecule large-conductance, calcium-activated potassium (“BK”) channel activator that works by binding to BK channels and increasing their activation to correct specific synaptic dysfunctions that underlie many core symptoms of FXS.
Health Technology Insights: Johnson & Johnson Seeks EMA Approval to Extend AKEEGA Use for Prostate Cancer
“We are grateful to the EMA for recognizing the importance of developing treatments for FXS and supporting the development and path to market for our novel drug, SPG601,” said Dr. Stella Sarraf, Spinogenix Chief Executive Officer and Founder. “We want to ensure that every person living with this disabling condition can access treatment. Having already obtained ODD and Fast Track designations from the U.S. FDA, this new grant from the EMA takes us one step forward to achieving our mission to help patients across the globe.”
Topline results from a Phase 2 randomized, double-blind, placebo-controlled, crossover study of SPG601 therapy in adult men with FXS were announced earlier this year. The study met its primary goal, significantly reducing high-frequency gamma band activity in the FXS subjects, a key indicator that occurs in FXS patients at the expense of normal brain activity levels that are used for learning and memory.
“Currently, FXS has no approved treatment, making indications like the EMA’s ODD crucial for advancing therapies and accelerating development,” said Dr. Craig Erickson, Spinogenix Chief Medical Advisor and principal investigator of the recently completed Phase 2 study conducted at Cincinnati Children’s Hospital. “SPG601 has the potential to improve the underlying synaptic deficits central to this condition, offering immense hope to the whole patient community.”
Dr. Erickson will present results from the Phase 2 trial at the Cincinnati Fragile X Family Conference, taking place on Saturday, July 12 at Cincinnati Children’s Hospital. Families and researchers can attend to learn about the latest research and treatments and receive advice on planning and managing behaviors.
The EMA grants ODD to drugs and biologics intended for the treatment, prevention or diagnosis of a life-threatening or chronically debilitating disease that affects fewer than five in 10,000 people in the European Union, and with either no currently approved method of diagnosis, prevention or treatment or with significant benefit to those affected by the disease. Companies that secure ODD benefit from a 10-year period of market exclusivity following authorization, protocol assistance, and regulatory fee reductions.
Health Technology Insights: ACA Pharma Secures Fast-track Approval For Eagle Pharmaceuticals’ Ryanodex In Macau
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
